menu
Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug
Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug
Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain.

Owing to the ever-increasing number of start-ups that areinvolved in R&D of novel biologics, there is an enormous opportunity forthe CMOs in this domain. It is worth emphasizing that, since 2000, more than115 new CMOs have been established in order to serve to the growing demand fornovel biologics that have specific manufacturing requirements. The contemporarycontract services market features a mix of large and small-sized CMOs and ischaracterized by multiple mergers and acquisitions as stakeholders strive tobroaden their respective service portfolios. This has enabled several CMOs tooffer end-to-end services, ranging from drug development, including preliminaryR&D, preclinical and clinical trials, to commercial scale production andregulatory filings

 

To order this 750+ page report, which features 200+ figuresand 250+ tables, please visit this link

 

The USD 13.9 billion(by 2030) financial opportunity within the biopharmaceutical manufacturing markethas been analyzed across the following segments:

§ Commonly Outsourced Business Operations

§ Active Pharmaceutical Ingredients (API)

§ Finished Dosage Formulations (FDF)

§ Types of Expression System

§ Mammalian

§ Microbial

§ Others

§ Company Size

§ Small

§ Mid-Sized

§ Large and Very Large

§ Scale of Operation

§ Preclinical

§ Clinical

§ Commercial

§ Key Geographical Region 

§ North America

§ Europe

§ Asia-Pacific

§ Rest of the World 

 

The BiopharmaContract Manufacturing Market (3rd Edition), 2019-2030. report features thefollowing companies, which we identified to be key players in this domain:

§  3P Biopharmaceuticals

§  Abzena

§  Albany Molecular Research

§  BioVectra

§  BioXcellence (Boehringer Ingelheim)

§  Celonic

§  Charles River Laboratories

§  ChemPartner

§  Cobra Biologics

§  CordenPharma

§  Cytovance Biologics

§  GE Healthcare

§  Goodwin Biotechnology

§  Grand River Aseptic Manufacturing

§  IDT Biologika

§  KBI BioPharma

§  Kemwell Biopharma

§  LFB Biomanufacturing

§  Meridian Life Science

§  Patheon

§  Pfizer CentreOne

§  PX'Therapeutics

§  Samsung BioLogics

§  Sanofi, CEPiA

§  Thermo Fisher Scientific

§  Vetter Pharma International

 

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Competitive Landscape

5. Biopharmaceutical Contract Manufacturing in NorthAmerica

6. Biopharmaceutical Contract Manufacturing in Europe

7. Biopharmaceutical Contract Manufacturing in Asia PacificAnd the Rest of The World

8. Biopharmaceutical Contract Manufacturing in Asia PacificAnd the Rest of The World

 

9. Case Study: Outsourcing of Biosimilars

10. Case Study: Comparison of Small Molecule and   Large Molecule Drugs / Therapies

 

11. Case Study on In-House Manufacturing

12. Collaborations

13. Recent Developments

14. Capacity Analysis

 

15. Demand Analysis

 

16. Market Forecast

 

17. SWOT Analysis

 

18.  Future of TheBiopharmaceutical CMO Market

 

19.  Survey Analysis

 

20. Interview Transcripts

 

21. Appendix 1: List of Non-Industry Players

 

22. Appendix 1: List of Non-Industry Players

 

23. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com